Robert C. Stanton, MD American Journal of Kidney Diseases

Slides:

Advertisements

Similar presentations

Date of download: 7/1/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Decline in Estimated Glomerular Filtration Rate and.

Advertisements

Commentary on ‘The DOPPS Practice Monitor for US Dialysis Care: Potential Impact of Recent Guidelines and Regulatory Changes on Management of Mineral.

Hypertension Awareness, Treatment, and Control in Chronic Kidney Disease Pantelis A. Sarafidis, MD, PhD, Suying Li, PhD, Shu-Cheng Chen, MS, Allan J.

Renal Function Testing

Lilia Cervantes, Monica Grafals, Rudolph A. Rodriguez

Sumeska Thavarajah, MD, Daphne H. Knicely, MD, Michael J. Choi, MD

Diagnosis and Management of Chronic Kidney Disease

Core Assessment of Predonation Kidney Function: Clarification of the 2017 KDIGO Living Donor Guideline Krista L. Lentine, MD, PhD, Andrew S. Levey, MD,

Metabolic Complications in Elderly Adults With CKD

Development of Reduced Kidney Function in Rheumatoid Arthritis

Jessica W. Weiss, MD, Eric S. Johnson, PhD, Amanda Petrik, MS, David H

Care of the Undocumented Immigrant in the United States With ESRD

Surviving the First Year of Peritoneal Dialysis: Enduring Hard Times

A Decade After the KDOQI CKD Guidelines

World Kidney Day 2014: CKD and the Aging Population

Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in Patients With Type 2 Diabetes Mellitus George L. Bakris, MD Mayo Clinic.

Management of Acute Kidney Injury: Core Curriculum 2018

The Challenge of Providing Renal Replacement Therapy in Developing Countries: The Latin American Perspective Gregorio T. Obrador, MD, MPH, Ximena Rubilar,

Recognition for Conservative Care in Kidney Failure

CKD and Poverty: A Growing Global Challenge

Andrew Narva American Journal of Kidney Diseases

Advances in CKD Detection and Determination of Prognosis: Executive Summary of the National Kidney Foundation–Kidney Early Evaluation Program (KEEP) 2012.

Shared Primacy of Sodium and Potassium on Cardiovascular Risk

Chapter 3: Management of progression and complications of CKD

GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration

Comprehensive Public Health Strategies for Preventing the Development, Progression, and Complications of CKD: Report of an Expert Panel Convened by the.

Daniel E. Weiner, MD, MS American Journal of Kidney Diseases

Erratum American Journal of Kidney Diseases

Glycemic Management in ESRD and Earlier Stages of CKD

Salt and Hypertension American Journal of Kidney Diseases

Is There Any Reason to Stent Atherosclerotic Renal Artery Stenosis?

Greg A. Knoll, MD, MSc American Journal of Kidney Diseases

This Month in AJKD American Journal of Kidney Diseases

The Kidney Early Evaluation Program (KEEP): Program Design and Demographic Characteristics of the Population Claudine T. Jurkovitz, MD, MPH, Yang Qiu,

Joseph A. Vassalotti, MD, Lesley A. Stevens, MD, MS, Andrew S

Robert C. Stanton, MD American Journal of Kidney Diseases

Dorothea Nitsch, MD, MSc American Journal of Kidney Diseases

Management of Heart Failure in Advancing CKD: Core Curriculum 2018

Geriatrics American Journal of Kidney Diseases

A New Era of Renal Denervation Trials for Patients With Hypertension?

Hypertension After Kidney Transplant

IgA Nephropathy: Progress Before and Since Berger

Polyunsaturated Fatty Acids and Kidney Disease

Kidney Disease Among African Americans: A Population Perspective

Plasma Parathyroid Hormone Level and Prevalent Cardiovascular Disease in CKD Stages 3 and 4: An Analysis From the Kidney Early Evaluation Program (KEEP)

Beef Tea, Vitality, Creatinine, and the Estimated GFR

A Timely Evaluation of the Psychometric Properties of the KDQOL-36

Christina L. Klein, MD, Daniel C. Brennan, MD, FACP

American Journal of Kidney Diseases

Quiz Page April 2008 American Journal of Kidney Diseases

Evidence and Outcomes in CKD

Daniel T. Lackland, DrPH, David J.P. Barker, MD, PhD

Daniel E. Weiner, MD, MS, Mark J. Sarnak, MD, MS

George L. Bakris, MD, John M. Burkart, MD, Eric D

Lesley A. Stevens, MD, MS, Nicholas Stoycheff, MD

Lynda Anne Szczech, Ira L. Lazar Kidney International

Michael J. Germain, MD, Sara N. Davison, MD, Alvin H. Moss, MD

Arnold S. Relman, MD, American Journal of Kidney Diseases

Lesley A. Stevens, MD, MS, Josef Coresh, MD, PhD, Andrew S. Levey, MD

Removal of Dabigatran by Hemodialysis

KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline

In the Literature: Cognitive Impairment in Hemodialysis Patients

Achieving Fairness in Access to Kidney Transplant: A Work in Progress

Commentary on ‘The DOPPS Practice Monitor for US Dialysis Care: Potential Impact of Recent Guidelines and Regulatory Changes on Management of Mineral.

James F. Winchester, MD, Thomas H. Hostetter, MD, Timothy W. Meyer, MD

Clinical Practice Recommendations For Peritoneal Dialysis Adequacy

National Kidney Foundation's Kidney Early Evaluation Program (KEEP) Annual Data Report 2009: Executive Summary Peter A. McCullough, MD, MPH, Joseph A.

Clinical Practice Guidelines for Peritoneal Dialysis Adequacy

Sumeska Thavarajah, MD, Daphne H. Knicely, MD, Michael J. Choi, MD

Update on Cystatin C: Incorporation Into Clinical Practice

Presentation transcript:

Clinical Challenges in Diagnosis and Management of Diabetic Kidney Disease Robert C. Stanton, MD American Journal of Kidney Diseases Volume 63, Issue 2, Pages S3-S21 (February 2014) DOI: 10.1053/j.ajkd.2013.10.050 Copyright © 2014 National Kidney Foundation, Inc. Terms and Conditions

Figure 1 Incidence counts and rates for the major causes of end-stage kidney disease. Diabetes mellitus has become the main cause for new cases of end-stage kidney disease. Reproduced from the US Renal Data System 2012 Annual Data Report.1 American Journal of Kidney Diseases 2014 63, S3-S21DOI: (10.1053/j.ajkd.2013.10.050) Copyright © 2014 National Kidney Foundation, Inc. Terms and Conditions

Figure 2 Prevalence counts and rates for the major causes of end-stage kidney disease. Diabetes mellitus has become the main cause for all cases of end-stage kidney disease. Reproduced from the US Renal Data System 2012 Annual Data Report.1 American Journal of Kidney Diseases 2014 63, S3-S21DOI: (10.1053/j.ajkd.2013.10.050) Copyright © 2014 National Kidney Foundation, Inc. Terms and Conditions

Figure 3 Prevalence counts of end-stage kidney disease by race. Although the white population has the highest number of cases, the prevalence rate is significantly higher in African Americans and Native Americans. Reproduced from the US Renal Data System 2012 Annual Data Report.1 American Journal of Kidney Diseases 2014 63, S3-S21DOI: (10.1053/j.ajkd.2013.10.050) Copyright © 2014 National Kidney Foundation, Inc. Terms and Conditions

Figure 4 Prevalence counts of end-stage kidney disease in the Hispanic population. The Hispanic population has a significantly higher prevalence than the non-Hispanic population. Data supplied by the US Renal Data System.1 American Journal of Kidney Diseases 2014 63, S3-S21DOI: (10.1053/j.ajkd.2013.10.050) Copyright © 2014 National Kidney Foundation, Inc. Terms and Conditions

Figure 5 Rate of decline in glomerular filtration rate slows as mean arterial pressure is decreased. Adapted from Bakris et al70 with permission of National Kidney Foundation. American Journal of Kidney Diseases 2014 63, S3-S21DOI: (10.1053/j.ajkd.2013.10.050) Copyright © 2014 National Kidney Foundation, Inc. Terms and Conditions

Figure 6 There is an increase in all-cause mortality in people with cardiovascular disease when systolic blood pressure is <115mm Hg. Reproduced with permission of American Medical Association from Cooper-DeHoff et al.68 American Journal of Kidney Diseases 2014 63, S3-S21DOI: (10.1053/j.ajkd.2013.10.050) Copyright © 2014 National Kidney Foundation, Inc. Terms and Conditions

Figure 7 Increases in serum creatinine level of up to 30% from a baseline up to 3mg/dL within the first 4 months of starting angiotensin-converting enzyme inhibitor treatment correlated with slower rates of decline in renal function. Adapted from Bakris et al70 with permission of National Kidney Foundation. American Journal of Kidney Diseases 2014 63, S3-S21DOI: (10.1053/j.ajkd.2013.10.050) Copyright © 2014 National Kidney Foundation, Inc. Terms and Conditions

Figure 8 In the RENAAL Study, the greater the initial decline in glomerular filtration rate, the slower the rate of progression of diabetic kidney disease. Reproduced with permission of Macmillan Publishers Ltd from Holtkamp et al.75 American Journal of Kidney Diseases 2014 63, S3-S21DOI: (10.1053/j.ajkd.2013.10.050) Copyright © 2014 National Kidney Foundation, Inc. Terms and Conditions